Login

Financial Snapshot

Revenue
TTM
$865.8M
Gross Margin
TTM
88.25%
Net Income
TTM
$495.9M
Current Assets
2026 Q1
$1.122B
Current Liabilities
2026 Q1
$1.127B
Current Ratio
2026 Q1
99.61%
Total Assets
2026 Q1
$2.003B
Total Liabilities
2026 Q1
$1.515B
Book Value
2026 Q1
488.0M
Cash
2026 Q1
$572.8M
P/E
TTM
27.13
Free Cash Flow
TTM
$45.00M

Stock Price

Loading...
Market Cap: $13.453 Billion

About Ascendis Pharma A/S

Ascendis Pharma A/S is a DK-based company operating in Biotechnology industry. Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The firm scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.

Industry: Pharmaceutical Preparations Peers: IO Biotech Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support